ARTICLE | Company News

AbbVie buys United's Priority Review voucher

August 20, 2015 2:35 AM UTC

United Therapeutics Corp. (NASDAQ:UTHR) said it sold a rare pediatric disease Priority Review voucher to AbbVie Inc. (NYSE:ABBV) for $350 million. AbbVie spokesperson Adelle Infante declined to disclose the company's plans for the voucher.

United received the voucher in March when FDA approved Unituxin dinutuximab to treat high-risk pediatric neuroblastoma (see BioCentury Extra, March 10). ...